Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperphosphatemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Hyperphosphatemia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-004748-36 Sponsor Protocol Number: PA-CL-03A Start Date*: 2008-10-30
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label, randomized, active controlled multi center phase II dose finding study to evaluate the ability of PA21 to lower serum phosphate levels and the tolerability in patients with chronic k...
    Medical condition: Hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-003565-40 Sponsor Protocol Number: PA-CL-03 Start Date*: 2007-12-18
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease ...
    Medical condition: patients with chronic kidney disease undergoing hemodialysis hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004729-41 Sponsor Protocol Number: ACT 401 Start Date*: 2009-10-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double bli...
    Medical condition: Hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001185-17 Sponsor Protocol Number: IH 002 Start Date*: 2006-05-26
    Sponsor Name:Ineos Healthcare Ltd
    Full Title: A long-term, open-label continuation study to assess the safety of Alpharen™ in haemodialysis subjects with hyperphosphataemia.
    Medical condition: Hyperphosphataemia in haemodialysis subjects
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003240-20 Sponsor Protocol Number: 16-058 Start Date*: 2017-10-12
    Sponsor Name:RWTH Aachen, represented by the rector, himself represented by the dean of the Medical Faculty
    Full Title: Velphoro and impact on the oral cavity and gut microbiome
    Medical condition: Hyperphosphatemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004959-38 Sponsor Protocol Number: SPD405-319 Start Date*: 2007-05-17
    Sponsor Name:Shire Development Inc
    Full Title: A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal...
    Medical condition: Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003364-64 Sponsor Protocol Number: SPD405-403 Start Date*: 2007-05-08
    Sponsor Name:Shire Development Inc
    Full Title: A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis
    Medical condition: Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000488-95 Sponsor Protocol Number: 6520-9961-04 Start Date*: 2013-08-28
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG
    Full Title: Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with hyperphosphatemia
    Medical condition: Dialysis-dependent patients with hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004319-33 Sponsor Protocol Number: D5613C00001 Start Date*: 2014-04-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in E...
    Medical condition: Hyperphosphatemia in patients with end-stage renal disease on hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002589-20 Sponsor Protocol Number: CALMAG-01 Start Date*: 2007-12-14
    Sponsor Name:Fresenius Medical Care Deutschland GmbH
    Full Title: Evaluation of Calcium Acetate/Magnesium Carbonate (OsvaRen®) compared to Sevelamer (Renagel®) in Haemodialysis Patients
    Medical condition: Elevated serum phosphate levels (hyperphosphataemia) in patients with chronic renal failure on dialysis (haemodialysis, peritoneal dialysis)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004735-30 Sponsor Protocol Number: IH 003 Start Date*: 2006-11-20
    Sponsor Name:Ineos Healthcare Ltd
    Full Title: An open label, dose-ranging study to establish the tolerability of Alpharen™ in haemodialysis subjects with hyperphosphataemia.
    Medical condition: Hyperphosphataemia in haemodialysis subjects
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004340-35 Sponsor Protocol Number: CAMG-14-I Start Date*: 2015-03-03
    Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Full Title: Randomized controlled trial of two different combinations of Calcium-containing Phosphate binders (Ca-PiB) plus non-Calcium-non-Aluminum containing Phosphate binders (no-Ca-Al-PiB): a pharma-econom...
    Medical condition: Hyperphosphatemia associated with Chronic Kidney Disease (CKD) in patients undergoing hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002095-10 Sponsor Protocol Number: MV-2-2017 Start Date*: 2017-09-13
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney D...
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001787-23 Sponsor Protocol Number: CSBR759A2201 Start Date*: 2008-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels i...
    Medical condition: Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) GB (Completed) FI (Completed) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004730-25 Sponsor Protocol Number: ACT 402 Start Date*: 2009-05-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) LT (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006320-20 Sponsor Protocol Number: CT.SVL.PD.10.001 Start Date*: 2012-05-17
    Sponsor Name:Synthon BV
    Full Title: A multicenter, randomized, double-blind, multiple dose, crossover study to evaluate the safety and equivalence of serum phosphate control of a new sevelamer carbonate tablet formulation in compari...
    Medical condition: Evaluation of the safety and equivalence of serum phosphate control of a sevelamer carbonate tablet formulation in comparison with Renvela® in chronic kidney disease patients on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002583-27 Sponsor Protocol Number: MCI-196-E15 Start Date*: 2013-07-11
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000171-17 Sponsor Protocol Number: SPD405-207 Start Date*: 2012-10-02
    Sponsor Name:Shire Pharmaceutical Development Ltd.
    Full Title: A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, compare the Efficacy, Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonat...
    Medical condition: Treatment of Hyperphosphataemia.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) Outside EU/EEA CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-006097-15 Sponsor Protocol Number: CSBR759A2304 Start Date*: 2009-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, placebo-controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo
    Medical condition: hyperphosphataemia in chronic kidney disease patients on renal replacement therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022012-40 Sponsor Protocol Number: PA-CL-05B Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 compared with Sevelamer Carbonate in D...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    15.0 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 18:19:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA